|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1987-7-10
|
|
pubmed:abstractText |
Administration in vivo of recombinant interleukin 2 (rIL-2) to mice induces a polyclonal IgM response. When co-administered with a specific antigen, rIL-2 can enhance concentrations of murine IgM antibodies specific for the antigen by fivefold within 7 d of initial treatment. IgM antibodies that are induced after injection of rIL-2 include antibodies specific for J5, a cell wall core lipopolysaccharide (LPS) antigen that is shared by the different members of the Enterobactericeae family. We report here that mice pretreated with rIL-2 or immunized with J5 antigen 7 d before bacterial challenge were protected from septic death that is caused by intraperitoneal challenges with Escherichia coli. Optimal protection was provided by a combined J5 antigen and rIL-2 treatment. Acquisition of the rIL-2 and J5 antigen-induced protection against lethal bacterial infection coincided temporally with maximal serum IgM titers that also contained IgM antibodies specific for the J5 antigen. In passive immunization experiments, the affinity-purified IgM fraction in sera of rIL-2-treated animals was identified as necessary and sufficient for protection. The IgM-depleted serum had no protective effect. The nonspecific augmentation of host-defense mechanisms without the induction of endotoxin manifestations makes rIL-2 a potential candidate to any alternative LPS-containing vaccines for the prevention of bacterial infections by gram-negative organisms since the core LPS antigen is shared among gram-negative bacteria.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-14299610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-2857730,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-2933466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-2993418,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3486940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3514463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3514464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3516883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3874257,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3903508,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-3905964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-411630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-418134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-4558866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-4577881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-4583074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-4947185,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-5476392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-5804498,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6201551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6203984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6367046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6602767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6609363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-6752708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3294901-7042755
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1756-63
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:3294901-Animals,
pubmed-meshheading:3294901-Antibodies, Bacterial,
pubmed-meshheading:3294901-Antigens, Bacterial,
pubmed-meshheading:3294901-Escherichia coli,
pubmed-meshheading:3294901-Escherichia coli Infections,
pubmed-meshheading:3294901-Female,
pubmed-meshheading:3294901-Immunization,
pubmed-meshheading:3294901-Immunoglobulin M,
pubmed-meshheading:3294901-Interleukin-2,
pubmed-meshheading:3294901-Lipopolysaccharides,
pubmed-meshheading:3294901-Mice,
pubmed-meshheading:3294901-Mice, Inbred BALB C,
pubmed-meshheading:3294901-Peritonitis,
pubmed-meshheading:3294901-Recombinant Proteins,
pubmed-meshheading:3294901-Sepsis
|
|
pubmed:year |
1987
|
|
pubmed:articleTitle |
Administration in vivo of recombinant interleukin 2 protects mice against septic death.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
